Jiangbo Jin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jiangbo Jin has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
Yunhe Huang
Jiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Diseases, the Department of Thoracic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
2 shared publications- Bentong Yu
Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China
1 shared publication Guobin Xie
Jiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Diseases, the Department of Thoracic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publication- Guobin Xie
Nanchang University
1 shared publication Jie Yang
Jiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Diseases, the Department of Thoracic Surgery, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publicationLonghua Sun
Jiangxi Provincial Key Laboratory of Respiratory Diseases, Jiangxi Institute of Respiratory Diseases, Departments of Pulmonary and Critical Care Medicine, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China
1 shared publication
Latest Publications
- Open Access
- 19 January 2026
- Published by Springer Nature in Cell & Bioscience
- Vol. 16 (1)
The mutual regulation of SOX12 and RNF168 modulates cisplatin resistance in esophageal squamous cell carcinoma cells by regulating DNA damage repair
Resistance to chemotherapy drugs is one of the significant factors for limited treatment options and poor prognosis in esophageal cancer. A study has found
- 19 January 2026
- Published by Springer Nature in Cell & Bioscience
- Vol. 16 (1)
Open AccessThe mutual regulation of SOX12 and RNF168 modulates cisplatin resistance in esophageal squamous cell carcinoma cells by regulating DNA damage repair
Resistance to chemotherapy drugs is one of the significant factors for limited treatment options and poor prognosis in esophageal cancer. A study has found
- Open Access
- 1 January 2025
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 103, 1-13
TRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12
Tumor necrosis factor receptor-associated factor 7 (TRAF7), a member of the tumor necrosis factor receptor superfamily, is known as an E3 ubiquitin ligase and has been shown to contribute to the progression of various cancers. However, the function of TRAF7 in esophageal squamous cell carcinoma (ESCC) remains unclear. Here, our findings demonstrate a marked downregulation of TRAF7 protein expression in ESCC cell lines compared to non-neoplastic esophageal epithelial cells. Overexpression of TRAF7 inhibited cell proliferation and migration of ESCC cells, as well as promoted cell apoptosis and blocked cell cycle at the G2/M phase. In this study, we observed that TRAF7 interacted with the SOX12 protein and promoted ubiquitin-proteasome-mediated degradation of SOX12 via K48-linked ubiquitination in ESCC cells. Rescue experiments further confirmed that TRAF7’s inhibitory effects on tumor cell proliferation and migration in ESCC cells partly depended on SOX12. In summary, our research reveals that TRAF7 functions as a tumor suppressor partially by promoting K48-linked ubiquitination-mediated degradation of the SOX12 protein.
- 1 January 2025
- Published by Canadian Science Publishing in Biochemistry and Cell Biology
- Vol. 103, 1-13
Open AccessTRAF7 inhibits proliferation and migration of esophageal squamous cell carcinoma by ubiquitination-mediated degradation of SOX12
Tumor necrosis factor receptor-associated factor 7 (TRAF7), a member of the tumor necrosis factor receptor superfamily, is known as an E3 ubiquitin ligase and has been shown to contribute to the progression of various cancers. However, the function of TRAF7 in esophageal squamous cell carcinoma (ESCC) remains unclear. Here, our findings demonstrate a marked downregulation of TRAF7 protein expression in ESCC cell lines compared to non-neoplastic esophageal epithelial cells. Overexpression of TRAF7 inhibited cell proliferation and migration of ESCC cells, as well as promoted cell apoptosis and blocked cell cycle at the G2/M phase. In this study, we observed that TRAF7 interacted with the SOX12 protein and promoted ubiquitin-proteasome-mediated degradation of SOX12 via K48-linked ubiquitination in ESCC cells. Rescue experiments further confirmed that TRAF7’s inhibitory effects on tumor cell proliferation and migration in ESCC cells partly depended on SOX12. In summary, our research reveals that TRAF7 functions as a tumor suppressor partially by promoting K48-linked ubiquitination-mediated degradation of the SOX12 protein.